{
    "info": {
        "nct_id": "NCT03123783",
        "official_title": "A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination With Nivolumab in Subjects With Non-small Cell Lung Cancer and Subjects With Metastatic Melanoma",
        "inclusion_criteria": "* Histologically or cytologically confirmed, immunotherapy na誰ve or PD-1/PD-L1 pre-treated, metastatic or locally advanced non-small cell lung cancer not amenable to curative treatment. Subjects may be treatment naive or could have received one prior platinum based chemotherapy for non-small cell lung cancer and subjects with a documented activating mutation (e.g., EGFR, ALK, ROS) must also have received the appropriate therapy and progressed\n* Histologically or cytologically confirmed unresectable or metastatic melanoma that progressed during treatment with an anti-PD-1/PD-L1 therapy and had confirmation of PD>=4 weeks later. Subjects with BRAF activating mutation could have also received a BRAF inhibitor and/or MEK inhibitor regimen prior to anti-PD-1/PD-L1 therapy.\n* Measurable disease by RECIST 1.1\n* ECOG performance status of 0 or 1\n* Adequate bone marrow, liver and kidney function\n* Negative pregnancy test for women of child bearing potential\n* Agreement to use effective methods of contraception per the protocol requirements\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Previous exposure to any immunomodulatory agents (e.g., anti- CD40, anti-PD-1/PD-L1, anti-CTLA-4, IDO inhibitors) except PD-1/PD-L1 targeting agents in the subsets of patients that must have previous treatment with anti-PD-1/PD-L1 therapy\n* Second malignancy (solid or hematologic) within the past 3 years except locally curable cancers that have been apparently cured\n* Active, known, clinically serious infections within the 14 days prior to first dose of investigational product\n* Use of systemic corticosteroids or other systemic immunosuppressive drugs\n* Active, known or suspected autoimmune disease\n* History of (non-infectious) pneumonitis that required corticosteroids or current pneumonitis\n* History of interstitial lung disease\n* History of life-threatening toxicity related to prior anti-PD-1/PD-L1 treatment for subjects with metastatic melanoma or NSCLC.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* ECOG performance status of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease by RECIST 1.1",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease by RECIST 1.1",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically confirmed unresectable or metastatic melanoma that progressed during treatment with an anti-PD-1/PD-L1 therapy and had confirmation of PD>=4 weeks later. Subjects with BRAF activating mutation could have also received a BRAF inhibitor and/or MEK inhibitor regimen prior to anti-PD-1/PD-L1 therapy.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed unresectable or metastatic melanoma",
                    "criterion": "melanoma",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "resectability",
                            "expected_value": "unresectable"
                        },
                        {
                            "requirement_type": "metastatic status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "progressed during treatment with an anti-PD-1/PD-L1 therapy",
                    "criterion": "disease progression during anti-PD-1/PD-L1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy type",
                            "expected_value": "anti-PD-1/PD-L1"
                        }
                    ]
                },
                {
                    "exact_snippets": "had confirmation of PD>=4 weeks later",
                    "criterion": "progressive disease confirmation interval",
                    "requirements": [
                        {
                            "requirement_type": "confirmation interval",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with BRAF activating mutation could have also received a BRAF inhibitor and/or MEK inhibitor regimen prior to anti-PD-1/PD-L1 therapy",
                    "criterion": "BRAF activating mutation and prior BRAF/MEK inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": "BRAF activating mutation"
                        },
                        {
                            "requirement_type": "prior therapy",
                            "expected_value": [
                                "BRAF inhibitor",
                                "MEK inhibitor"
                            ]
                        },
                        {
                            "requirement_type": "therapy sequence",
                            "expected_value": "prior to anti-PD-1/PD-L1 therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate bone marrow, liver and kidney function",
            "criterions": [
                {
                    "exact_snippets": "Adequate bone marrow ... function",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... liver ... function",
                    "criterion": "liver function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... kidney function",
                    "criterion": "kidney function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically confirmed, immunotherapy na誰ve or PD-1/PD-L1 pre-treated, metastatic or locally advanced non-small cell lung cancer not amenable to curative treatment. Subjects may be treatment naive or could have received one prior platinum based chemotherapy for non-small cell lung cancer and subjects with a documented activating mutation (e.g., EGFR, ALK, ROS) must also have received the appropriate therapy and progressed",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed",
                    "criterion": "non-small cell lung cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "immunotherapy na誰ve or PD-1/PD-L1 pre-treated",
                    "criterion": "immunotherapy treatment history",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": [
                                "immunotherapy na誰ve",
                                "PD-1/PD-L1 pre-treated"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "metastatic or locally advanced non-small cell lung cancer not amenable to curative treatment",
                    "criterion": "disease stage and treatment amenability",
                    "requirements": [
                        {
                            "requirement_type": "disease stage",
                            "expected_value": [
                                "metastatic",
                                "locally advanced"
                            ]
                        },
                        {
                            "requirement_type": "curative treatment amenability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects may be treatment naive or could have received one prior platinum based chemotherapy for non-small cell lung cancer",
                    "criterion": "prior platinum-based chemotherapy for NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "number of prior treatments",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "treatment"
                            }
                        },
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "treatment naive",
                                "platinum based chemotherapy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects with a documented activating mutation (e.g., EGFR, ALK, ROS) must also have received the appropriate therapy and progressed",
                    "criterion": "activating mutation targeted therapy history",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": "documented activating mutation (e.g., EGFR, ALK, ROS)"
                        },
                        {
                            "requirement_type": "appropriate targeted therapy received",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "progression after therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Negative pregnancy test for women of child bearing potential",
            "criterions": [
                {
                    "exact_snippets": "Negative pregnancy test",
                    "criterion": "pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "women of child bearing potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "reproductive potential",
                            "expected_value": "child bearing potential"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agreement to use effective methods of contraception per the protocol requirements",
            "criterions": [
                {
                    "exact_snippets": "Agreement to use effective methods of contraception per the protocol requirements",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "effectiveness",
                            "expected_value": "per the protocol requirements"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Active, known or suspected autoimmune disease",
            "criterions": [
                {
                    "exact_snippets": "Active, known or suspected autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": [
                                "active",
                                "known",
                                "suspected"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of interstitial lung disease",
            "criterions": [
                {
                    "exact_snippets": "History of interstitial lung disease",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active, known, clinically serious infections within the 14 days prior to first dose of investigational product",
            "criterions": [
                {
                    "exact_snippets": "Active, known, clinically serious infections within the 14 days prior to first dose of investigational product",
                    "criterion": "clinically serious infections",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "awareness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically serious"
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of life-threatening toxicity related to prior anti-PD-1/PD-L1 treatment for subjects with metastatic melanoma or NSCLC.",
            "criterions": [
                {
                    "exact_snippets": "History of life-threatening toxicity related to prior anti-PD-1/PD-L1 treatment",
                    "criterion": "life-threatening toxicity related to prior anti-PD-1/PD-L1 treatment",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of (non-infectious) pneumonitis that required corticosteroids or current pneumonitis",
            "criterions": [
                {
                    "exact_snippets": "History of (non-infectious) pneumonitis that required corticosteroids",
                    "criterion": "history of non-infectious pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "required corticosteroids"
                        }
                    ]
                },
                {
                    "exact_snippets": "current pneumonitis",
                    "criterion": "current pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Second malignancy (solid or hematologic) within the past 3 years except locally curable cancers that have been apparently cured",
            "criterions": [
                {
                    "exact_snippets": "Second malignancy (solid or hematologic) within the past 3 years",
                    "criterion": "second malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "solid",
                                "hematologic"
                            ]
                        },
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except locally curable cancers that have been apparently cured",
                    "criterion": "locally curable cancers that have been apparently cured",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous exposure to any immunomodulatory agents (e.g., anti- CD40, anti-PD-1/PD-L1, anti-CTLA-4, IDO inhibitors) except PD-1/PD-L1 targeting agents in the subsets of patients that must have previous treatment with anti-PD-1/PD-L1 therapy",
            "criterions": [
                {
                    "exact_snippets": "Previous exposure to any immunomodulatory agents (e.g., anti- CD40, anti-PD-1/PD-L1, anti-CTLA-4, IDO inhibitors) except PD-1/PD-L1 targeting agents",
                    "criterion": "previous exposure to immunomodulatory agents",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "agent_types",
                            "expected_value": [
                                "anti-CD40",
                                "anti-CTLA-4",
                                "IDO inhibitors"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "except PD-1/PD-L1 targeting agents in the subsets of patients that must have previous treatment with anti-PD-1/PD-L1 therapy",
                    "criterion": "previous exposure to PD-1/PD-L1 targeting agents",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "patient_subset",
                            "expected_value": "patients that must have previous treatment with anti-PD-1/PD-L1 therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of systemic corticosteroids or other systemic immunosuppressive drugs",
            "criterions": [
                {
                    "exact_snippets": "Use of systemic corticosteroids",
                    "criterion": "systemic corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other systemic immunosuppressive drugs",
                    "criterion": "systemic immunosuppressive drug use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}